Ubs Group Ag Alkermes Plc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
2 transactions
Others Institutions Holding ALKS
# of Institutions
360Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$821 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$535 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$366 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$357 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$259 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.63B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...